+49 711 500 989 80
deen

Bone marrow cancer: Potential drug targets



Bone marrow cancer: Potential drug targets

New research finds that patients with ASXL1-mutant chronic myelomonocytic leukemia — an uncommon type of cancer of the bone marrow — have distinctive epigenetic changes that can activate harmful genes and cause the cancer to grow faster. The ASXL1 genetic mutation also can transform the disease into the more aggressive acute myeloid leukemia.

Materials provided by Mayo Clinic. Original written by Susan Murphy. Note: Content may be edited for style and length.




Source link aaaaa

Related posts

27th May 2022

High cost of cancer care in the U.S. doesn't reduce mortality rates

Read more
27th May 2022

T cell warriors need their R & R

Read more
27th May 2022

New cancer subtype may illuminate treatment strategy

Read more